

UPHEALTH GROUP LIMITED

Registration No. 201835258H
(Incorporated in the Republic of Singapore)

RESULTS OF ANNUAL GENERAL MEETING HELD ON 29 APRIL 2026

Pursuant to Rule 704(15) of the Listing Manual Section B: Rules of Catalist of the Singapore Exchange Securities Trading Limited (the “**Catalist Rules**”), the Board of Directors (the “**Board**” or the “**Directors**”) of UpHealth Group Limited (the “**Company**”) is pleased to announce that:

- (a) The resolutions set out in the Notice of Annual General Meeting (the “**AGM**”) dated 14 April 2026 voted by way of poll were duly passed at the AGM held today.
- (b) The breakdown of all valid votes cast at the AGM are as follows:

Resolution number and details	Total number of shares represented by votes for and against the relevant resolution	For		Against	
		Number of shares	As a percentage of total number of votes for and against the resolution (%)	Number of shares	As a percentage of total number of votes for and against the resolution (%)
<u>Ordinary Business</u>					
<u>Ordinary Resolution 1</u> To receive and adopt the Directors' Statement and Audited Financial Statements for the financial year ended 31 December 2025, together with the Auditors' Report thereon.	117,562,800	117,510,200	99.96	52,600	0.04
<u>Ordinary Resolution 2</u> To re-elect Mr. Gavin Mark McIntyre, retiring by rotation under Regulation 94 of the Company's Constitution.	117,562,800	117,510,200	99.96	52,600	0.04
<u>Ordinary Resolution 3</u> To re-elect Mr. Ravi Chidambaram, retiring by rotation under Regulation 94 of the Company's Constitution.	117,562,800	117,510,200	99.96	52,600	0.04

Resolution number and details	Total number of shares represented by votes for and against the relevant resolution	For		Against	
		Number of shares	As a percentage of total number of votes for and against the resolution (%)	Number of shares	As a percentage of total number of votes for and against the resolution (%)
<u>Ordinary Resolution 4</u> To approve Directors' fees of S\$180,000 for the financial year ending 31 December 2026, payable by the Company in arrears not later than 31 December 2026.	117,562,800	117,510,200	99.96	52,600	0.04
<u>Ordinary Resolution 5</u> To re-appoint Foo Kon Tan LLP as auditors of the Company for the financial year ending 31 December 2026 and to authorise the Directors of the Company to fix their remuneration.	117,562,800	117,510,200	99.96	52,600	0.04
<u>Special Business:</u>					
<u>Ordinary Resolution 6</u> To authorise the Directors to issue and allot shares and/or instruments pursuant to Section 161 of the Companies Act 1967.	117,562,800	117,510,200	99.96	52,600	0.04
<u>Ordinary Resolution 7</u> To authorise the Directors to grant options and issue shares under the Company's Employee Share Option Scheme.	117,562,800	117,510,200	99.96	52,600	0.04

- (c) Details of parties who are required to abstain from voting on any resolution(s), including the number of shares held and the individual resolution(s) on which they are required to abstain from voting.

No party is required to abstain from voting on the above resolutions.

- (d) Name of firm and/or person appointed as scrutineer

Cypress Pines Asia Advisory Pte. Ltd. was appointed as the scrutineer of the AGM.

- (e) Re-election of Directors

For Resolution 2, Mr. Gavin Mark McIntyre having been re-elected as a Director of the Company at the AGM, remains as the Chairman of the Audit and Risk Committee and a member of the Remuneration Committee and the Nominating Committee of the Company. He is considered an Independent Director pursuant to Rule 704(7) of the Catalist Rules of the SGX-ST.

For Resolution 3, Mr. Ravi Chidambaram having been re-elected as a Director of the Company at the AGM, remains as the Chairman of the Remuneration Committee and a member of the Audit and Risk Committee and the Nominating Committee of the Company. He is considered an Independent Director pursuant to Rule 704(7) of the Catalist Rules of the SGX-ST.

BY ORDER OF THE BOARD

Marat Devlet-Kildeev
Chief Executive Officer and Executive Director

29 April 2026

This announcement has been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "**Exchange**") and the Exchange assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr Shervyn Essex, 16 Collyer Quay, #10-00 Collyer Quay, Singapore 049318, sponsorship@ppcf.com.sg.